XML 73 R56.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands |  |  |  | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | ---
May 30, 2024 USD ($) | Oct. 30, 2023 USD ($) | Mar. 22, 2021 USD ($) item | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($)
Agreements |  |  |  |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  |  |  |  | $ 37,000 | $ 14,650 |
Short-term royalty and commercial payment receivables |  |  |  | $ 14,257 |  | 14,257 |  | $ 14,215
Long-term royalty and commercial payment receivables |  |  |  | 69,731 |  | 69,731 |  | 57,952
Trade and other receivables, net |  |  |  | 526 |  | 526 |  | 1,004
Viracta |  |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |  |
Reduction in long-term royalty receivable balance due to receipt of payment |  |  |  |  |  | 8,500 |  |
Viracta | Royalty Purchase Agreement |  |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |  |
Number of drug candidates | item |  |  | 2 |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  | $ 13,500 |  |  |  |  |
Maximum amount of potential milestones, potential royalties on sales and other payments receivable |  |  | 54,000 |  |  |  |  |
Amount of maximum consideration retained |  |  | 5,000 |  |  |  |  |
Maximum amount of potential regulatory and commercial milestones receivable |  |  | 57,000 |  |  |  |  |
Acquisition of royalty and commercial payment receivables, Long-Term |  |  | $ 13,500 |  |  |  |  |
Amount of milestone payments earned under agreement |  | $ 5,000 |  |  |  | 9,000 |  |
Reduction in long-term royalty receivable balance due to receipt of payment |  | $ 5,000 |  |  |  | 8,500 |  |
Income from purchased receivables |  |  |  | 900 | $ 0 | 900 | $ 0 |
Sale of priority review voucher to undisclosed buyer | $ 108,000 |  |  |  |  |  |  |
Long-term royalty and commercial payment receivables |  |  |  | 0 |  | 0 |  |
Amount of allowance for credit losses |  |  |  |  |  |  |  | 0
Trade and other receivables, net |  |  |  | $ 400 |  | 400 |  | $ 0
Viracta | Royalty Purchase Agreement | OJEMDA |  |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |  |
Income from purchased receivables |  |  |  |  |  | 500 |  |
Viracta | Royalty Purchase Agreement | Priority review voucher. |  |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |  |
Income from purchased receivables |  |  |  |  |  | $ 8,100 |  |

X
- Definition Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of drug candidates under the terms of the agreement. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of income that is not accounted for under Topic 606, in accordance with the cost recovery method. + References No definition available. + Details
Name: | xoma_IncomeNotFromContractWithCustomerCostRecoveryMethod
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_LongTermRightsReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. + References No definition available. + Details
Name: | xoma_MaximumConsiderationRetained
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone achieved. + References No definition available. + Details
Name: | xoma_MilestoneAchieved
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum amount of potential milestones, potential royalties on sales, and other payments, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount representing sale of priority review voucher. + References No definition available. + Details
Name: | xoma_PriorityReviewVoucherSale
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Decrease in long-term rights receivable due to receipt of royalty and commercial payments. + References No definition available. + Details
Name: | xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. + References No definition available. + Details
Name: | xoma_RegulatoryAndCommercialMilestonesReceivableMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RightsReceivableCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_TovorafenibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_PriorityReviewVoucherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |